Infusion solution 50 micrograms \/ ml
(Clear colorless solution)<\/p>\n\n\n\n
Aggrastat is used to facilitate the blood supply to the heart and helps prevent chest pain and heart attack. It works by preventing the formation of blood clots. This medicine can also be used by patients who have had dilation of the heart’s vessels by balloon rupture ( percutaneous coronary intervention, PCI). This procedure is usually performed with the help of an implant of a small tube to facilitate blood flow to the heart.<\/p>\n\n\n\n
Aggrastat is intended for use with acetylsalicylic acid and unfractionated heparin.<\/p>\n\n\n\n
Talk to your doctor before using Aggrastat if you have or have had:<\/p>\n\n\n\n
Aggrastat can generally be used with other medicines. Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription, as some medicines may affect each other. It is especially important to tell your doctor if you are taking other medicines that prevent the blood from clotting, such as warfarin.<\/p>\n\n\n\n
Intake of food and drink does not affect this medicine.<\/p>\n\n\n\n
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<\/p>\n\n\n\n
Due to your medical condition, you should not drive or use machines while using Aggrastat.<\/p>\n\n\n\n
You are responsible for assessing whether you are fit to drive a motor vehicle or perform work that requires increased attention. One of the factors that can affect your ability in these respects is the use of drugs due to their effects and\/or side effects. Descriptions of these effects and side effects can be found in other sections. Read all the information in this leaflet for guidance. If you are not sure, talk to your doctor or pharmacist.
<\/p>\n\n\n\n
Aggrastat contains sodium<\/strong><\/p>\n\n\n\n This medicine contains approximately 917 mg sodium per 250 ml of infusion bag. This should be considered by patients on a low-salt diet. Aggrastat should be prescribed by a qualified doctor who has experience in treating heart attacks.<\/p>\n\n\n\n You have been given, or will be given, Aggrastat intravenously. Your doctor will decide on the appropriate dose, based on your general condition and your weight.<\/p>\n\n\n\n Use in children is not recommended.<\/p>\n\n\n\n Your doctor will decide when a dose should be given.<\/p>\n\n\n\n Your doctor will decide when to stop treatment. However, if you want to end treatment earlier, you should discuss other options with your doctor.<\/p>\n\n\n\n If you have any further questions on the use of this product, ask your doctor or pharmacist.<\/strong><\/p>\n\n\n\n Like all medicines, this medicine can cause side effects, although not everybody gets them.<\/p>\n\n\n\n Bleeding is the most common side effect during treatment with Aggrastat and can occur throughout the body. This can be serious, and in rare cases lead to a fatal outcome.<\/p>\n\n\n\n If side effects occur, medical attention may be needed. If you get any of the following symptoms while using Aggrastat, contact your doctor immediately:<\/p>\n\n\n\n Reporting of side effects<\/em><\/p>\n\n\n\n If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Medical Products Agency, www.lakemedelsverket.se. By reporting side effects, you can help increase drug safety information. <\/p>\n\n\n\n Your doctor and pharmacist know how to store and take care of Aggrastat after use.<\/p>\n\n\n\n Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n Do not use this medicine after the expiry date which is stated on the bag after EXP.<\/p>\n\n\n\n The expiration date is the last day of the specified month.<\/p>\n\n\n\n Do not freeze.<\/p>\n\n\n\n Store in the original package (250 ml infusion bag in foil bag). Sensitive to light. Do not use this medicine if you notice that there are visible particles or that the solution is discolored before use. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.<\/p>\n\n\n\n The active substance is tirofiban.<\/p>\n\n\n\n 1 ml solution for infusion contains 56 micrograms tirofiban hydrochloride monohydrate, equivalent to 50 micrograms tirofiban.<\/p>\n\n\n\n The other ingredients are Sodium chloride, sodium citrate dihydrate, anhydrous citric acid, water for injections, hydrochloric acid, and\/or sodium hydroxide (for adjustment ).<\/p>\n\n\n\n Aggrastat is a clear, colorless solution available as follows:<\/p>\n\n\n\n 250 ml Freeflex\u00ae infusion bag (not PVC plastic), colorless, multilayer polyolefin film with polyolefin sealed bag with an injection port. It is packed in a pre-printed foil bag. Pack sizes: 1 or 3 infusion bags of 250 ml solution for infusion. Not all pack sizes may be marketed.<\/p>\n\n\n\n Correvio<\/p>\n\n\n\n 15 rue du Bicentenaire<\/p>\n\n\n\n 92800 Puteaux<\/p>\n\n\n\n France<\/p>\n\n\n\n <\/p>\n\n\n\n Manufacturer<\/strong><\/p>\n\n\n\n Arvato Distribution GmbH,<\/p>\n\n\n\n Gottlieb Daimler Stra\u00dfe 1,<\/p>\n\n\n\n 33428 Harsewinkel,<\/p>\n\n\n\n Germany This leaflet was last modified on 27 May 2019<\/p>\n\n\n\n The following information is intended for healthcare professionals only:<\/strong> Aggrastate should be co-administered with unfractionated heparin and oral platelet aggregation inhibitors, including acetylsalicylic acid (ASA). Dosage and route of administration<\/strong><\/p>\n\n\n\n In patients treated with an early invasive strategy for NSTE-ACS but who are not expected to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Aggrastat is given intravenously at an initial infusion rate of 0.4 micrograms\/kg\/min for 30 minutes. . After the initial infusion, treatment with Aggrastat should be continued with a maintenance infusion at a rate of 0.1 micrograms\/kg\/min. Aggrastat should be given with unfractionated heparin(usually an intravenous bolus dose)of 50-60 units (E) \/ kg at the start of treatment with Aggrastat and thereafter approximately 1,000 U \/ h titrated based on the activated partial thromboplastin time (APT time), which should be approximately twice the normal value, and oral treatment with platelet aggregation inhibitors, including but not exclusively ASA unless contraindicated.<\/p>\n\n\n\n In NSTE-ACS patients scheduled to be treated with PCI within 4 hours of diagnosis or in patients with acute myocardial infarction scheduled for primary PCI, Aggrastat should be administered with an initial bolus dose of 25 micrograms\/kg administered over 3 minutes followed by a maintenance infusion of 0, 15 micrograms\/kg\/min for 12-24 hours and up to 48 hours.<\/p>\n\n\n\n Aggrastat should be given in combination with unfractionated heparin ( dosing as above) and oral platelet aggregation inhibitors, including but not limited to ASA unless contraindicated. No dose adjustment is required for the elderly. Patients with severe renal failure<\/em><\/p>\n\n\n\n In severe renal failure ( creatinine clearance <30 mL\/min), Aggrastat dose a is reduced by<\/p>\n\n\n\n 50%. Pediatric population<\/em><\/p>\n\n\n\n The safety and efficacy of Aggrastat in children have not been established.<\/p>\n\n\n\n No data are available. Start and treatment time with<\/em> Aggrastat<\/p>\n\n\n\n In patients treated with an early invasive strategy for NSTE-ACS but who are not expected to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Aggrastat should be administered intravenously at an initial infusion rate of 0.4 micrograms\/kg\/min after diagnosis. . The recommended time for the maintenance dose is at least 48 hours. Infusion of Aggrastat and unfractionated heparin may continue during coronary angiography and should be maintained for at least 12 hours, but not more than 24 hours after angioplasty\/atherectomy. When a patient is clinically stable and no coronary surgery is planned by the treating physician, the infusion should be given one is interrupted. The total treatment time should not exceed 108 hours.<\/p>\n\n\n\n If a patient who has been diagnosed with NSTE-ACS and treated with an invasive approach then undergoes angiography within 4 hours of diagnosis, Aggrastat should be given with a bolus dose of 25 micrograms\/kg intravenously at the start of PCI with continuous infusion for 12-24 hours and up to 48 hours. In patients with acute myocardial infarction planned for primary PCI, the bolus infusion should be started as soon as possible after diagnosis. Concomitant treatment (unfractionated heparin, oral antithrombocyte aggregation inhibitors, including ASA)<\/em><\/p>\n\n\n\n Treatment with unfractionated heparin begins with an intravenous bolus dose of 50-60 U \/ kg and then continues with a maintenance dose of 1,000 U per hour. The heparin dose is titrated to maintain an APT time of approximately twice the normal value.<\/p>\n\n\n\n If not contraindicated, all patients should receive treatment with oral platelet aggregation inhibitors before starting treatment with Aggrastat. This medication should be continued at least as long as the infusion of Aggrastat is ongoing.<\/p>\n\n\n\n Most studies examining the administration of Aggrastat as an adjuvant to PCI have used ASA in combination with clopidogrel as an oral platelet aggregation inhibitor. The efficacy of Aggrastat in combination with either prasugrel or ticagrelor has not been established in randomized controlled trials. <\/p>\n\n\n\n If angioplasty (PCI) is required, heparin delivery should be discontinued after PCI and the catheter should be removed as soon as coagulation has returned to normal, ie when activated clotting time (ACT) is less than 180 seconds (usually 2-6 hours after heparin release ). Incompatibilities<\/strong><\/p>\n\n\n\n Incompatibility has been observed with diazepam. Therefore, Aggrastat and diazepam should not be administered via the same intravenous line.<\/p>\n\n\n\n No incompatibilities have been observed with Aggrastat and the following intravenous preparations: atropine sulfate, dobutamine, dopamine, adrenaline hydrochloride, furosemide, heparin, lidocaine, midazolam hydrochloride, morphine sulfate, glyceryl trinitrate, potassium chloride, propranolol hydrochloride, and injection. Instructions for handling<\/strong><\/p>\n\n\n\n Check the expiration date.<\/p>\n\n\n\n Do not draw the solution directly from the infusion bag with a syringe. To open: Pull the notch in the dustproof foil or plastic bag (250 ml solution for infusion ) and remove the infusion bag. Check for leaks by squeezing the bag tightly. If leakage is detected, the solution should be discarded as sterility may have been compromised.<\/strong><\/p>\n\n\n\n Do not use unless the solution is clear and the seal is intact.<\/strong> Do not add additional medicines or draw solution directly from the infusion bag with a syringe. NOTE: Do not connect in series. Such use may result in air embolism due to residual air from an emptied bag being drawn in by liquid from another bag. Preparation for delivery<\/strong><\/p>\n\n\n\n Used according to the dose calculation given below. The following table can be used as a guide for dose adjustment based on body weight:<\/p>\n\n\n\n Special storage instructions<\/strong><\/p>\n\n\n\n Do not use this medicine after the expiry date which is stated on the label and outer carton after EXP. The expiration date is the last day of the specified month.<\/p>\n\n\n\n Do not freeze. What the medicine looks like and the contents of the pack<\/strong><\/p>\n\n\n\n Aggrastat is a clear, colorless solution available as follows:<\/p>\n\n\n\n 250 ml Freeflex\u00ae TM<\/sup> (not PVC plastic), colorless, 3-layer polyolefin film with polyolefin sealed bag with an injection port. It is packed in a pre-printed foil bag. Pack sizes: 1 or 3 infusion bags of 250 ml solution for infusion. Not all pack sizes may be available. Special instructions for destruction and handling<\/strong><\/p>\n\n\n\n Any unused product or waste material should be disposed of in accordance with local requirements.<\/p>\n","protected":false},"excerpt":{"rendered":" Aggrastat is used to facilitate the blood supply to the heart and helps prevent chest pain and heart attack. It works by preventing the formation of blood clots. This medicine can also be used by patients who have had dilation of the heart’s vessels by balloon rupture ( percutaneous coronary intervention, PCI). This procedure is usually performed with the help of an implant of a small tube to facilitate blood flow to the heart.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2201,2200],"tags":[11411,11414,11415,11410,11406,11409,11413,11412,11407,11408],"class_list":["post-5003","post","type-post","status-publish","format-standard","hentry","category-a","category-medicines","tag-aggrastat","tag-benefits-of-aggrastat","tag-side-effects-of-aggrastat","tag-side-effects-of-tirofiban","tag-tirofiban","tag-tirofiban-benefits","tag-what-aggrastat-is-used-for","tag-what-is-aggrastat","tag-what-is-tirofiban","tag-what-tirofiban-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=5003"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5003\/revisions"}],"predecessor-version":[{"id":13031,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5003\/revisions\/13031"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=5003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=5003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=5003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/p>\n\n\n\n3. How to use Aggrastat<\/h2>\n\n\n\n
Use for children<\/h2>\n\n\n\n
If you forget to use Aggrastat<\/h2>\n\n\n\n
If you stop using Aggrastat<\/h2>\n\n\n\n
4. Possible side effects<\/h2>\n\n\n\n
The following is a list of side effects that have occurred in some patients after treatment with Aggrastat. The side effects are listed by descending frequency:
Very common <\/strong>(may affect more than 1 user in 10)<\/em><\/li>
Common <\/strong>(may affect up to 1 in 10 people)<\/em><\/li>
Uncommon <\/strong>(may affect up to 1 in 100 people<\/em> )<\/li>
Has been reported <\/strong>(occurs in an unknown number of users)<\/em><\/li>
<\/li><\/ul>\n\n\n\n5. How to store Aggrastat<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n6. Contents of the packaging and other information<\/h2>\n\n\n\n
Content declaration<\/h2>\n\n\n\n
What the medicine looks like and the contents of the pack<\/h2>\n\n\n\n
<\/p>\n\n\n\nMarketing Authorisation Holder<\/h2>\n\n\n\n
<\/p>\n\n\n\nOther sources of information<\/h2>\n\n\n\n
<\/p>\n\n\n\nThis product is only intended for use in hospitals by specialists accustomed to treating acute heart disease.<\/h2>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n<\/a><\/td> 1. Identify the blue<\/strong> infusion port.<\/td><\/tr> <\/a><\/td> 2. Break off the blue<\/strong> warranty sealed port cover from the Freeflex\u00ae infusion port. The membrane under the protection is sterile – disinfection of the membrane is not necessary!<\/td><\/tr> <\/a><\/td> 3. Close the roller clamp. Slide the tip into the door until the blue plastic ring comes in contact with the shaft of the tip. Use a non-ventilated unit or close the vent valve.<\/td><\/tr>
<\/td>4. Hang the bag in the infusion stand. Press the drip chamber to get the liquid level. Fill the infusion line and prime it free of air bubbles. Connect and adjust the flow rate.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/p>\n\n\n\n
<\/th>0.4 micrograms \/ kg \/ min Dose adjustment<\/strong>Most patients<\/strong><\/th> 0.4 micrograms \/ kg \/ min Dose adjustment<\/strong>Severe renal failure<\/strong><\/th> 25 micrograms\/kg bolus adjustment most patients<\/strong><\/th> 25 micrograms \/ kg bolus adjustmentSevere renal failure<\/strong><\/th><\/tr><\/thead> Bodyweight (kg)<\/th> 30 minute initialinfusion rate (ml \/ hour)<\/td> Infusion rate during maintenance treatment
(ml \/ hour)<\/td>30 minute initial infusion rate
(ml \/ hour)<\/td>Infusion rate during maintenance treatment
(ml \/ hour)<\/td>Bolus(ml)<\/td> Infusion rate during maintenance treatment
(ml \/ hour)<\/td>Bolus(ml)<\/td> Infusion rate during maintenance treatment
(ml \/ hour)<\/td><\/tr>30-37<\/th> 16<\/td> 4<\/td> 8<\/td> 2<\/td> 17<\/td> 6<\/td> 8<\/td> 3<\/td><\/tr> 38-45<\/th> 20<\/td> 5<\/td> 10<\/td> 3<\/td> 21<\/td> 7<\/td> 10<\/td> 4<\/td><\/tr> 46-54<\/th> 24<\/td> 6<\/td> 12<\/td> 3<\/td> 25<\/td> 9<\/td> 13<\/td> 5<\/td><\/tr> 55-62<\/th> 28<\/td> 7<\/td> 14<\/td> 4<\/td> 29<\/td> 11<\/td> 15<\/td> 5<\/td><\/tr> 63-70<\/th> 32<\/td> 8<\/td> 16<\/td> 4<\/td> 33<\/td> 12<\/td> 17<\/td> 6<\/td><\/tr> 71-79<\/th> 36<\/td> 9<\/td> 18<\/td> 5<\/td> 38<\/td> 14<\/td> 19<\/td> 7<\/td><\/tr> 80-87<\/th> 40<\/td> 10<\/td> 20<\/td> 5<\/td> 42<\/td> 15<\/td> 21<\/td> 8<\/td><\/tr> 88-95<\/th> 44<\/td> 11<\/td> 22<\/td> 6<\/td> 46<\/td> 16<\/td> 23<\/td> 8<\/td><\/tr> 96-104<\/th> 48<\/td> 12<\/td> 24<\/td> 6<\/td> 50<\/td> 18<\/td> 25<\/td> 9<\/td><\/tr> 105-112<\/th> 52<\/td> 13<\/td> 26<\/td> 7<\/td> 54<\/td> 20<\/td> 27<\/td> 10<\/td><\/tr> 113-120<\/th> 56<\/td> 14<\/td> 28<\/td> 7<\/td> 58<\/td> 21<\/td> 29<\/td> 10<\/td><\/tr> 121-128<\/th> 60<\/td> 15<\/td> 30<\/td> 8<\/td> 62<\/td> 22<\/td> 31<\/td> 11<\/td><\/tr> 129-137<\/th> 64<\/td> 16<\/td> 32<\/td> 8<\/td> 67<\/td> 24<\/td> 33<\/td> 12<\/td><\/tr> 138-145<\/th> 68<\/td> 17<\/td> 34<\/td> 9<\/td> 71<\/td> 25<\/td> 35<\/td> 13<\/td><\/tr> 146-153<\/th> 72<\/td> 18<\/td> 36<\/td> 9<\/td> 75<\/td> 27<\/td> 37<\/td> 13<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n